Term
|
Definition
| drug that opposes or inhibits the effects of a particular nuerotransmitter on the postsynaptic cell |
|
|
Term
|
Definition
| a drug that facilitates the effects of a particular neurotransmitter on the postsynpatic cell |
|
|
Term
| ways that drugs can agonize |
|
Definition
| can stimulate release of NT's, can bind to receptor site to open ion transmitters, can inhibit reuptake of NT's, can inhibit deactivation of NT's, can promote synthesis of NT's, can block autoreceptors (autoreceptors regulate the amount of NT's that are released) to increase release of NT's (fig on pg. 96) |
|
|
Term
| ways that drugs can antagonize |
|
Definition
| block release of NT's, block receptor site, prevent synthesis of NT's, block transporter molecule from filling vesicles with NT's, can stimulate autoreceptors (which control how much NT's are released) to prevent synthesis/release (fig p.96) |
|
|
Term
|
Definition
| a drug that mimicks the effect of a NT. It binds with and activates a receptor and causes ion channels to open just as they do when the NT is present |
|
|
Term
| receptor blockers or direct antagonists |
|
Definition
| a drug that binds with a receptor but doesnt activate it, it prevents the natural NT from binding with the receptor and opening ion channels (wrong key for lock but blocks lock) |
|
|
Term
|
Definition
| binding of a drug to a site on a receptor (some receptors have multiple bidning sites); does not interfere with the binding site for the principle ligand |
|
|
Term
|
Definition
| a drug that attaches to a binding site on a receptor and interferes with the action of the receptor, does not interfere with the binding site for the principal ligand |
|
|
Term
|
Definition
| a drug that attaches to a binding site on a receptor and facilitates the action of the receptor; does not intere with the binding site for the principal ligand |
|
|
